The India Immune Repertoire Sequencing Market was valued at $5.8 Million in 2025 and projected to reach to $9.3 Million by 2030, representing a compound annual growth rate of 10.2%. India's immune repertoire sequencing market is poised for accelerated growth driven by rising healthcare expenditure, government initiatives supporting genomic medicine, and increasing collaboration between research institutions and diagnostic centers.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
India's immune repertoire sequencing market is valued at USD 5.8 million in 2025, with a projected CAGR of 10.2%, reaching USD 9.3 million by 2030, outpacing the global growth rate of 9.6%.
India's increasing investment in genomic research centers and diagnostic laboratories is driving adoption of advanced immune repertoire sequencing technologies across major metropolitan and tier-2 cities.
Growing incidence of autoimmune diseases, immunodeficiencies, and cancer-related immune complications in India is creating substantial demand for precision immunology diagnostics and personalized treatment approaches.
India's expanding academic institutions and biotech startups are increasingly leveraging immune repertoire sequencing for vaccine development, immunotherapy research, and clinical immunology applications.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | TCR KITS (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 9.6% from 2025 to 2030 |
| Largest Segment | ASSAY KITS & REAGENTS (Product) |
| Market Size Base Year (Billions) | ~USD 0.35 (2025) |
| Revenue Forecast (Billions) | ~USD 0.56 (2030) |
| Segments Covered | Product, Type |
2 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 2.6 | 2.6 | 2.9 | 3.2 | 3.5 | 3.8 | 4.2 | 4.7 | 10.2 |
| OTHER END USERS | 1.6 | 1.7 | 1.8 | 2 | 2.1 | 2.3 | 2.6 | 2.8 | 9.3 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 2.4 | 2.4 | 2.6 | 2.9 | 3.2 | 3.5 | 3.9 | 4.3 | 10.4 |
| TOTAL | 6.6 | 6.7 | 7.3 | 8 | 8.8 | 9.7 | 10.7 | 11.8 | 10 |
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 0.9 | 0.6 | 0.5 | 0.5 | 0.5 | 0.6 | 0.7 | 0.9 | 11 |
| OTHER END USERS | 0.6 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 | 9.8 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 1.4 | 1 | 0.8 | 0.8 | 0.8 | 0.9 | 1.1 | 1.4 | 11.1 |
| TOTAL | 2.8 | 2 | 1.7 | 1.6 | 1.6 | 1.8 | 2.1 | 2.8 | 10.8 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| PACBIO | United States | Public Company | Long-read sequencing instruments (Revio, Sequel, Vega),Long-read consumables (SMRT cells, library prep, binding and sequencing kits),Short-read sequencing (Onso and related consumables), |
| OXFORD NANOPORE TECHNOLOGIES PLC | United Kingdom | Public Company | PromethION (2/24/48) instruments and consumables,MinION Mk 1D and related consumables,GridION / GridION Q systems and consumables, |
| 10X GENOMICS | United States | Public Company | Chromium single-cell instruments and consumables,Visium spatial instruments and consumables,Xenium in situ instruments and consumables, |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and infectious-disease diagnostics,Oncology and sexual & reproductive health assays, |
| AGILENT TECHNOLOGIES | United States | Public Company | Life Sciences and Diagnostics (instruments, reagents, genomics, pathology, CDMO, biomolecular analysis),Agilent CrossLab (services, consumables, software, asset management),Applied Markets (GC, MS, spectroscopy, vacuum, remarketed instruments), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and related solutions),Life Sciences (research and genomic tools),Diagnostics (clinical instruments and consumables), |
| TAKARA BIO INC. | Japan | Private Company | Genetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (including COVID-19 testing), |
| ADAPTIVE BIOTECHNOLOGIES | United States | Public Company | clonoSEQ MRD diagnostics,Life sciences research immunosequencing,Pharma and biotech drug discovery partnerships, |
| PERSONALIS, INC. | United States | Public Company | Pharma and biotech translational research / clinical trial services (ImmunoID NeXT and exome-based services),MRD and therapy monitoring (NeXT Personal, NeXT Personal Dx),Clinical tumor profiling and Dx (NeXT Dx and related tests), |
Illumina, Inc. is a United States-based public company founded in 1998 that employs 8,625 people. The company operates in the life sciences and genomics sector.
Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. It is a major provider of analytical instruments, reagents, and laboratory services.
PacBio is a United States-based public company founded in 2000 with 485 employees. The company specializes in DNA sequencing technology and solutions.
Oxford Nanopore Technologies PLC is a United Kingdom-based public company founded in 2005 with 1,316 employees. It develops nanopore-based DNA and RNA sequencing technologies.
10X Genomics is a United States-based public company founded in 2012 with 1,178 employees. The company provides solutions for single-cell and spatial genomics analysis.
QIAGEN is a Netherlands-based public company founded in 1984 with 5,500 employees. It develops and manufactures molecular diagnostics and life sciences products.
Agilent Technologies is a United States-based public company founded in 1999 with 18,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees. It operates across multiple sectors including life sciences, diagnostics, and environmental solutions.
Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company develops and manufactures molecular biology reagents and biotechnology products.
Adaptive Biotechnologies is a United States-based public company founded in 2009 with 624 employees. The company develops immune-driven diagnostics and therapeutics using T-cell and B-cell receptor sequencing.
Personalis, Inc. is a United States-based public company founded in 2011 with 260 employees. The company offers precision medicine and genomic analysis services.
India's immune repertoire sequencing market is valued at USD 5.8 million in 2025, with expectations to grow to USD 9.3 million by 2030.
India's immune repertoire sequencing market is projected to grow at a compound annual growth rate (CAGR) of 10.2% from 2025 to 2030.
India's market growth is driven by expanding biotechnology infrastructure, government support for genomic research, rising prevalence of immune-related disorders, and increasing adoption of precision medicine approaches.
India's 10.2% CAGR outpaces the global average of 9.6%, positioning India as a high-growth market within the Asia Pacific region for immune repertoire sequencing technologies.
Key applications in India include vaccine development, cancer immunotherapy, infectious disease management, and clinical diagnostics for immune-related conditions.
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global IRS market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
The market for the companies offering IRS is arrived at by secondary data available through paid and unpaid sources, analyzing the product and service portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives. Secondary data was analyzed to arrive at the overall size of the global IRS market, which was validated through primary research.
Extensive primary research was conducted after acquiring basic knowledge about the global IRS market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical & biotechnology companies, and experts from the supply side, such as C-level and D-level executives and managers. These interviews were conducted across major regions: North America, Europe, the Asia Pacific, and the Rest of the World (including Latin America, the Middle East, and Africa). This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
The global size of the IRS market was estimated and validated through multiple approaches, such as the top-down and bottom-up approaches. These methods were also used extensively to estimate the size of various market subsegments.

After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Immune repertoire refers to the diverse collection of T-cell and B-cell receptors within the adaptive immune system, which enables pathogen recognition and targeted immune responses. The IRS market encompasses technologies, products, and services that analyze the diversity and functional dynamics of T-cell and B-cell receptor repertoires within the adaptive immune system.
This market includes instruments, software, assays, kits, and reagents for immune receptor profiling, alongside presequencing, sequencing, and data analysis services that support research applications, drug discovery & development, and clinical diagnostics utilizing advanced methods such as NGS and PCR by various end users.
Full forecast, segment splits, and company analysis for all Immune Repertoire Sequencing Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report